Last year’s landmark case of “Baby KJ”—the first patient to receive a personalized CRISPR‑based gene therapy—showcased both the promise and the persistent challenges of genome editing. While CRISPR systems can act as remarkably precise molecular scissors, their active enzymes don’t always switch off cleanly. Lingering Cas activity can nick unintended DNA or RNA targets, raising the risk of harmful mutations in healthy genes. For CRISPR to reach its full therapeutic potential, researchers need reliable ways to keep these editors in check. That’s where anti‑CRISPRs come in. These phage‑derived proteins act as natural off‑switches for CRISPR–Cas systems, blocking nuclease activity through mechanisms ranging from competitive inhibition to disruption of effector complex formation. But despite their utility, anti‑CRISPRs (Acrs) are notoriously difficult to find. In the past decade, only 118 experimentally validated Acrs have been identified—an effort that could be compared to playing molecular “Where’s Waldo.” A team of researchers from Monash University and the University of Melbourne believes AI can change that. In a new study published in Nature Chemical Biology, titled “De novo design of potent CRISPR–Cas13 inhibitors,” the group describes a rapid, AI‑accelerated strategy for designing entirely new anti‑CRISPR proteins. “We leveraged de novo protein design to create new‑to‑nature protein inhibitors of CRISPR–Cas, which we call artificial intelligence (AI)-designed Acrs (AIcrs),” the authors wrote. The team focused on Cas13a from Leptotrichia buccalis, an RNA‑targeting CRISPR effector for which no validated natural inhibitors exist. Using RoseTTAFold‑Diffusion (RFdiffusion) for protein generation and ProteinMPNN for inverse folding, the researchers computationally designed candidate…
